Apimeds Pharmaceuticals US, Inc. Material Event Summary

If you follow Apimeds Pharmaceuticals (APUS), you have likely seen the major headlines today. There is a lot of drama unfolding at the company. I have broken it down into plain English so you can understand what is happening and what it means for your investment.

1. What happened?

On March 20, 2026, Apimeds underwent a total leadership overhaul. Stockholders holding a majority of the voting power removed the entire Board of Directors, including CEO Dr. Vin Menon and CFO Erick Frim. The new board immediately appointed Youngjik Cho as the new CEO. This move effectively ends the tenure of the team that previously managed the company’s pharmaceutical research and development.

2. Why did it happen?

The majority stockholders acted due to a breakdown in corporate governance regarding the proposed merger with MindWave Innovations. They claim the former team failed to disclose critical facts about MindWave’s intellectual property value and cash availability. The board allegedly withheld information that could have changed the $15 million merger valuation, leading to a total loss of trust in Dr. Menon and his team.

3. What is the new plan?

New leadership is pivoting the company away from pharmaceuticals to focus on high-growth consumer sectors. They are launching a North American distribution arm for Korean cosmetics and a "Life4Cuts" automated photo booth franchise. To stabilize the company, the new board canceled the planned 1-for-10 reverse stock split, which was originally intended to keep the share price above the $1.00 minimum required for OTC market listing.

4. Why does this matter?

This is a high-stakes situation. The sudden removal of the board and allegations of wrongdoing create significant legal and operational risks. The former team plans to sue in the Delaware Court of Chancery to challenge the board's removal. This creates a "dual-board" risk where two groups claim to be in charge, which could potentially freeze bank accounts and halt business operations until a court decides who is in control.

5. Who is affected?

• Investors: Shareholders face extreme price volatility. Since the company is moving from drug development to retail, old valuation models based on pharmaceutical research no longer apply. If the new business plan fails to generate quick profit, the company risks being delisted.
• Employees: The shift from drug research to retail likely means a major staff restructuring. Scientific staff may face layoffs, while the company will need to hire for retail and logistics.
• The Business: Apimeds is transforming into a completely different entity. Moving from high-barrier pharmaceuticals to a competitive retail model carries significant risk and requires a completely different set of operational skills.

6. What happens next?

The company is in a "wait and see" period. The new board is currently trying to secure control of corporate records and assets while preparing for the expected lawsuit. You should watch the SEC EDGAR database for official updates; these filings will clarify if the MindWave merger is officially dead or if the new board plans to renegotiate.

7. What should investors know?

This is a volatile situation. When a company fights over leadership, the stock price rarely stays stable.

The bottom line: This is a corporate soap opera. The company has abandoned its pharmaceutical focus and is pivoting to unproven retail ventures. Until the legal threats are resolved and the new leadership proves they can generate revenue, the company remains highly speculative. Proceed with extreme caution and keep a close eye on official SEC filings for any signs of stability.

Disclaimer: I am here to help you understand the news. This is not financial advice. Please do your own research or talk to a professional before making any big moves with your money.